YD Bio stock
YDESNASDAQYD Bio Limited, HealthcareISIN KYG983011076
36Score 36 out of 100, Weak
Price and trend
59 / 100
Price history
−41% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.3% below it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 66% below its 52-week high. Largest decline in 1 year: 92% (September 2025 to July 2026).
Chart figures for advanced users
- SMA 50$5.49
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.27
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.90
- The lowest closing price of the last twelve months.
- Resistance$15.42
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- YD Bio Limited belongs to the Biotechnology industry (Taiwan) and, with a market value of $368.32M, is number 270 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $596.82K (up 16.9% year on year) and a loss of $8.31M.
- MEQIRI Score 36 out of 100 (Weak): rank 601 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $6.01M, financial debt $6.76K.
Weaknesses
- Volatile share priceVolatility 137% a year over the last 12 months.Stability 49
- Loss-makingLoss of $8.31M over the last 12 months.Fundamentals 21
- Negative free cash flowFree cash flow −$8.04M over the last 12 months.Fundamentals 21
The score is held back by fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 36.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
The share count in the financial statements does not match the market value (factor 0.1). Per-share figures such as the P/E and the fair value are therefore treated as not measured until the data match.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 16.9% on the prior year. Revenue turned from negative at the start of the period to positive ($596.82K in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −7%, operating −883%, net −1393%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated; no interest coverage is reported.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $128,525 in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
Sector comparison
702 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- NeurogeneNGNE $377.68M32
- CorMedixCRMD $377.25M56
- Contineum TherapeuticsCTNM $375.46M35
- Orchestra BioMed HoldingsOBIO $369.65M50
- AlectorALEC $364.75M71
- C4 TherapeuticsCCCC $363.75M34
- Sagimet BiosciencesSGMT $356.12M45
- PepGenPEPG $348.61M42
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.